Abstract 10415: Lipoprotein-Associated Phospholipase A2 is Not Associated With Impairments in Endothelial Function: The Multi-Ethnic Study of Atherosclerosis
Objectives: Higher levels of Lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with risk of cardiovascular events, but mechanisms underlying this are not well understood. Considering the enzyme is specific for vascular inflammation, Lp-PLA2 may relate to the development of endothelial dysfunction. We evaluated the cross-sectional relationship of Lp-PLA2 with endothelial function in a population-based cohort without clinical cardiovascular disease.
Methods: 2814 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) had Lp-PLA2 mass and activity measurement and brachial artery flow-mediated vasodilation (FMD) testing. Ankle-brachial index (ABI) and maximum common carotid artery intima-media thickness (CIMT) were also measured.
Results: In adjusted linear regression models, higher Lp-PLA2 mass or activity were not associated with lower endothelial function (Table). Amongst individuals with subclinical atherosclerosis (ABI<1.00 or CIMT 1 standard deviation above the mean), Lp-PLA2 mass and activity remained unassociated with endothelial function. Table estimates represent the difference in endothelial function per standard deviation increment in Lp-PLA2 mass or activity adjusted for age, gender, ethnicity, BMI, DM, smoking status, SBP, total and HDL cholesterol, medication use (statin, anti-hypertensive), and socioeconomic status.
Conclusions: Lp-PLA2 is not associated with endothelial dysfunction measured by FMD. Endothelial cells are key regulators of vascular homeostasis and their dysfunction is thought to precede atherosclerosis development. Results suggest Lp-PLA2 may have involvement in more downstream processes, such as plaque inflammation or necrotic core formation, related to the development of cardiovascular disease.
- © 2010 by American Heart Association, Inc.